Amarantus Bioscience Holdings Inc (AMBS)

[brickbybrick]

You'd have better luck upping it to .0525 as you'd get filled pretty quickly. What's an $5,000 extra when;

Downside half a cent. Upside $1.00.

.06 is a gift.

I'm betting that future events will make it worth much more than .172.

Buy all you can afford here. Triple your money with in three months.

.12-.15 range by the end of the month.

$29M market cap is too low based on the potential value of LymPro and MANF.

Nickle Dime Quarter Dollar AMBS's share price move over the next eighteen months.

So much potential for a nickle a share.

The share price will never go under four cents.

The current share price is a gift.

.10 by next week.

I think that Jason Napadano's current valuation of .20 is too low.

Buy rating and .20 price target. Up it goes.

It's only a matter of time before the share price triples and the shareholders convert the warrants and the company up lists to the NASDAQ.

Seems like a no brainer for you to make money on your beliefs.

The current market cap is less than $29M. Jason Napadano says it should be $90M.

I still think that anyone that is buying at the current share price will make a tremendous amount of profit over the next three years.

Positive validation results for "LymPro": .15 range.

Deal with BD: .25-.30 range.

I still think this is one p.r. away from tripling over night.

To get to 700M shares outstanding the share price would have to go above .10 which is about 100% upside from where it is currently which is a nice return for anyone buying now.

share price being in the .50 range by the end of 2014.

Jason Napadano says it's a "BUY" with a .20 price target which I think is too low.

I still think the right news doubles/triples the share price. That could happen at any time.

Current market cap is under $25,000,000. So much for potential for under a dime.

280% upside from now.

$50.00 within two years after the uplisting.

I agree that the share price could easily exceed .15 with the right news.

Take advantage of the cheap price before it gaps higher.

Market cap of about $32,000,000 substantially undervalues the company. Five times that amount when BD validates LymPro.

If you can afford to add shares at .05 or lower to average down I think you'll be in the green on the next news.

I still haven't found another stock trading at such a discount to its potential as AMBS. Not one.

Even if the company had 1,000,000,000 shares outstanding the current market cap at the current share price would undervalue the company by 70%.

Even with the maximum number of shares being issued the market cap based on the current share price substantially undervalues the company.

News of a grant or j.v./partnership triples the share price.

LOL